Trial · NCT07482605
Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion
NCT07482605, Phase 2, Not yet recruiting, Jiangmen Central Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion. Trials, record NCT07482605. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07482605
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion
- NCT number
- NCT07482605
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 63 participants, estimated
- Lead sponsor
- Jiangmen Central Hospital
- Conditions
- Lung Cancer (NSCLC), Malignant Pleural Effusions (Mpe)- Pleurodesis
- Interventions
- Furmonertinib, Thoracic Radiotherapy (TRT)
- First posted
- 2026-03-19
- Last updated
- 2026-07-17
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-Free Survival (PFS) | From date of first dose to date of first documented disease progression or death from any cause, assessed up to 24 months. | PFS defined as time from first dose of furmonertinib to disease progression per RECIST v1.1 or death from any cause, whichever occurs first. |
| Secondary | Overall Response Rate (ORR) | Evaluations are performed at 1 month post-radiotherapy, and subsequently every 3 months, with a total follow-up period of 18 months. | Proportion of subjects achieving complete response (CR) or partial response (PR) according to RECIST v1.1. |
| Secondary | Malignant pleural effusion recurrence rate | Evaluations are performed at 1 month post-radiotherapy, and subsequently every 3 months, with a total follow-up period of 18 months. | Rate of MPE recurrence during the entire follow-up period following fumonertinib and local radiotherapy. |
| Secondary | Disease Control Rate (DCR) | Evaluations are performed at 1 month post-radiotherapy, and subsequently every 3 months, with a total follow-up period of 18 months. | Proportion of subjects achieving CR, PR, or stable disease (SD) according to RECIST v1.1. |
| Secondary | Overall Survival (OS) | From date of first dose to date of death from any cause, assessed up to 36 months . | Time from first dose of furmonertinib to death from any cause. |
| Secondary | Adverse event | From date of first dose to 30 days after last dose . | Frequency, severity, and relationship of adverse events assessed by CTCAE v5.0. |
| Secondary | Peripheral Blood ctDNA Level | Next-generation sequencing (NGS) was used to detect circulating tumor DNA (ctDNA) in peripheral blood samples collected before the first furmonertinib treatment and 1 month after the completion of thoracic radiotherapy (2 time points in total). | Dynamic changes in circulating tumor DNA (ctDNA) concentration in peripheral blood measured by next-generation sequencing (NGS). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07482605
GET https://conductscience.org/api/trials/v1/NCT07482605/registered